Explore 3 Stock Ideas & Industry Insights Download Free Report

News

What Should Investors Expect When ProPhase Labs, Inc. (OTCQB:PRPH) Reports Q3 2026 Results on November 16, 2026?

The second quarter report, filed on August 19, 2026, showed net revenue of USD 1.01 million against USD 1.25 million a year earlier, driven by lower consumer supplement sales. Gross margin was 22.4% versus 58.9%, which the company tied to product mix. General and …

Vinay Lochav | 13 November 2026

What Should Investors Expect When Direct Digital Holdings, Inc. (NASDAQ:DRCT) Reports Q3 2026 Results on November 16, 2026?

The Rationale: Last Reported Quarter and Management Outlook for Direct Digital Holdings, Inc. (NASDAQ:DRCT)

Vinay Lochav | 13 November 2026

What Should Investors Expect When Sangamo Therapeutics, Inc. (OTCQB:SGMO) Reports Results on November 16, 2026?

The Rationale: Last Reported Quarter and Management Outlook for Sangamo Therapeutics, Inc. (OTCQB:SGMO)

Vinay Lochav | 13 November 2026

Top 5 Biopharma Stocks Reporting on November 16, 2026: Omeros (NASDAQ:OMER) Q2 Net Revenue USD 28.5 Million, Jade Biosciences (NASDAQ:JBIO) Q2 Net Loss USD 55.8 Million, MapLight (NASDAQ:MPLT) Q2 Net Loss USD 60.2 Million, Enanta (NASDAQ:ENTA) Q3 Revenue USD 14.4 Million, Fulcrum (NASDAQ:FULC) Cash USD 318.8 Million

Key Highlights28.5 is the USD million of net YARTEMLEARevenueOmeros Corporation (NASDAQ:OMER) reported for the second quarter of 2026, compared with USD 9.9 million in the first quarter, its first full launch quarter.461.2 is the USD million of cash, cash equivalents and investments Jade Biosciences, …

Vinay Lochav | 13 November 2026

Top 4 Clinical-Stage Biotech Stocks Reporting on November 16, 2026: Larimar (NASDAQ:LRMR) Cash USD 156.3 Million, Prelude (NASDAQ:PRLD) Q2 Revenue USD 5.7 Million, Lexeo (NASDAQ:LXEO) Cash USD 234.2 Million, ALX Oncology (NASDAQ:ALXO) Q2 Net Loss USD 18.0 Million

Key Highlights156.3 is the USD million of cash, cash equivalents and marketable securities Larimar Therapeutics, Inc. (NASDAQ:LRMR) held on June 30, 2026, which management projects will fund operations into the third quarter of 2027.13.9 is the USD million net loss Prelude Therapeutics (NASDAQ:PRLD) reported …

Vinay Lochav | 13 November 2026

Top 4 Late-Stage Biotech Stocks Reporting on November 16, 2026: Invivyd (NASDAQ:IVVD) Q2 PEMGARDA Revenue USD 14.3 Million, Unicycive (NASDAQ:UNCY) Cash USD 61.4 Million, NRx Pharmaceuticals (NASDAQ:NRXP) Cash USD 26.7 Million, Oncolytics Biotech (NASDAQ:ONCY) Q2 Net Loss USD 9.4 Million

Key Highlights14.3 is the USD million of PEMGARDA net productRevenueInvivyd, Inc. (NASDAQ:IVVD) reported for the second quarter of 2026, up from USD 11.8 million, alongside a net loss of USD 44.4 million.61.4 is the USD million of cash, cash equivalents and marketable securities Unicycive …

Vinay Lochav | 13 November 2026

Top 4 Small-Cap Biotech Stocks Reporting on November 16, 2026: OS Therapies (NYSEAMERICAN:OSTX) Q2 Net Operating Loss USD 8.576 Million, Aardvark (NASDAQ:AARD) Q2 Net Loss USD 14.4 Million, Kyntra Bio (NASDAQ:KYNB) Liquidity USD 95.7 Million, Daré Bioscience (NASDAQ:DARE) EPS Estimate -0.13

Key Highlights8.576 is the USD million net operating loss OS Therapies (NYSEAMERICAN:OSTX) reported for the second quarter of 2026, up 77.2%, calculated, from USD 4.839 million a year earlier, with 2.5-year overall survival of 75% versus 47%.73.9 is the USD million of cash and …

Vinay Lochav | 13 November 2026

Top 4 Micro-Cap and Restructuring Biotech Stocks Reporting on November 16, 2026: Lantern Pharma (NASDAQ:LTRN) Q2 Net Loss USD 7.1 Million, Skye Bioscience (NASDAQ:SKYE) Cash USD 10.1 Million, Karyopharm (NASDAQ:KPTI) Q2 Revenue USD 33.4 Million, Sangamo (OTCQB:SGMO) Sale Proceeds USD 163.55 Million

Key Highlights7.1 is the USD million net loss Lantern Pharma (NASDAQ:LTRN) reported for the second quarter of 2026, or 0.57 per share, including about USD 3.6 million ofWarrantexpense, with cash and marketable securities of USD 7.4 million.10.1 is the USD million of cash and …

Vinay Lochav | 13 November 2026

Top 5 Medical Technology and Diagnostics Stocks Reporting on November 16, 2026: SS Innovations (NASDAQ:SSII) Q2 Revenue USD 13.9 Million, Insight (NASDAQ:IMDX) Q2 Loss USD 11.3 Million, Xtant (NYSEAMERICAN:XTNT) Q2 Revenue USD 23.0 Million, Rapid (NASDAQ:RPID) Q2 Loss USD 12.9 Million, Vivos (NASDAQ:VVOS) Q2 Revenue USD 5.153 Million

Key Highlights13.9 is the USD million of record second quarterRevenueSS Innovations (NASDAQ:SSII) reported, with first-half revenue up 65.6% to USD 25.0 million and an installed base of 224 systems.18.7 is the USD million of cash, equivalents and restricted cash Insight Molecular (NASDAQ:IMDX) held at …

Vinay Lochav | 13 November 2026

Top 4 Digital Asset and Fintech Stocks Reporting on November 16, 2026: Antalpha Platform (NASDAQ:ANTA) Q2 Revenue USD 12.2 Million, Cypherpunk Technologies (NASDAQ:CYPH) Q2 Net Income USD 39.4 Million, Canton Strategic Holdings (NASDAQ:CNTN) Q2 Revenue USD 1.5 Million, Treasure Global (NASDAQ:TGL) Fiscal 2026 Revenue USD 5.17 Million

Key Highlights10 million to USD 12 million is the third quarter 2026Revenuerange guided by Antalpha PlatformHolding Company(NASDAQ:ANTA), compared with second quarter revenue of USD 12.2 million that fell 28% year over year.9:00 a.m. ET on November 16, 2026 is when Cypherpunk Technologies Inc. (NASDAQ:CYPH) …

Vinay Lochav | 13 November 2026
Support

Hi! How can we help you today?

Loading…